Journal of Nephrology & Therapeutics

Clinical Research & Development, Kibow Therapeutics, Inc 4781 West Chester Pike, Newtown Square, PA 19073, USA

Publications

• Mini Review   
  Targeting Inflammation to Slow CKD Progression- Role of Gut Microbiome Based Therapy
  Author(s): Emmanuel Anteyi*, Natarajan Ranganathan and Usha Vyas
  
  Chronic Kidney Disease (CKD) is a worldwide public health problem associated with high morbidity, mortality, and socioeconomic burden. Despite recent advances in pathogenesis and effective Standard of Care (SOC) therapy, the incidence of end stage renal disease remains high, attributed to the complex and diverse pathophysiological pathways in progression of CKD. Among the many pathogenetic pathways, inflammation plays the most central role in disease progression and related complications. Current SOC treatment to slow CKD progression has not adequately addressed these complex processes as a result of persistence of low-grade inflammation occurring at all stages of CKD. Previous attempts to address the inflammatory pathway with specific anti-inflammatory agents were, in certain cases discontinued for reasons ranging from drug safety to efficacy concerns, and bus.. Read More»
  DOI: 10.37421/2161-0959.2024.14.481

  Abstract HTML PDF